Use of opioid molecules for the treatment of dry eye and allergic eye conditions
Patent Information
- Application Number
- JP2021572550
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-07
- Filing Date
- 2020-06-05
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-06-05
AI Technical Summary
【0030】 同位体で標識された化合物および塩は、様々な方法で使用することができる。それらは、薬物および/または様々なタイプの試験(基質上の組織分布試験(tissue-on-substrate distribution test)など)に適することができる。例えば、トリチウムおよび/または炭素14で標識された化合物は、比較的簡単に調製でき、また検出性にも優れているため、基質上の組織分布試験などの様々なタイプの試験に特に有用である。例えば、重水素標識製品は治療上有用であり、重水素標識されていない化合物と比較して潜在的な治療上の利点を有する。一般に、重水素で標識された化合物および塩は、速度論的同位体効果(isotopic kinetic effect)のために同位体で標識されていないものよりも高い代謝安定性を有し得る。より高い代謝安定性は、in vivoでの半減期の延長やより少ない用量に直結し、それらが望まれる場合がある。同位体で標識された化合物および塩は、一般に、既知の合成スキームに記載されている手順に従って調製することができる。例えば欧州特許第3352757号などの世界的な文献に関連する記載がある。したがって、非重水素化メチルを重水素化メチルに置き換えることは容易である。ノスカピンは、白色の結晶性粉末の形態である。水に不溶性であり、ベンゼンやアセトンに可溶性である。酸を用いて形成される塩は右旋性である。
Smart Images

Figure 0007577279000001 
Figure 0007577279000002 
Figure 0007577279000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the use of the levorotatory and dextrorotatory enantiomers of the chemical compound: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one, for treating dry eye and allergic eye.
[0002] The present invention relates to the use of opioid molecules with activity in modulators of the transmembrane conductance regulator (CFTR) and in regulating the expression of CD63, for the treatment of dry eye and allergic eye, as well as pharmaceutical compositions and methods of treatment. [Background technology]
[0003] Xerophthalmia or dry eye syndrome is defined by the 2007 Dry Eye Workshop as a multifactorial disease of the tears and ocular surface with underlying pathology of the ocular surface resulting in symptoms of discomfort, visual disturbance and tear film instability. The disease is associated with increased osmolality of the tear film and inflammation of the ocular surface. The etiology is diverse and is usually differentiated between dry syndromes due to reduced tear flow (e.g. Gougerot-Sjogren syndrome) and dry syndromes due to excessive tear evaporation.
[0004] Meibomian gland dysfunction (MGD) is the most frequent cause of dry eye disease (DED). The 2011 workshop also defined meibomian gland dysfunction. Eyelid inflammation, microbial proliferation, associated skin disorders, and potentially serious corneal complications make MGD a complex multifactorial disorder. MGD is considered to be a heterogeneous disease resulting from a combination of five different pathophysiological mechanisms: eyelid inflammation, conjunctival inflammation, corneal involvement, microbiological changes, and DED resulting from tear film instability. The pathogenesis of both MGD and DED can be described as a "vicious circle": the pathophysiological mechanisms underlying DED and MGD interact with each other, resulting in a double vicious circle. This double vicious circle is the cause of dry eye and its difficult to treat.
[0005] Xerophthalmia (dry eye disease or DED) is a multifactorial and complex disease of the ocular surface that results in the loss of homeostasis of the tear film, causing a variety of ocular symptoms. The negative impact of DED on visual function, quality of life, and economic burden is well recognized (Non-Patent Document 1). In many patients, the disease is chronic and requires long-term treatment.
[0006] The prevalence of DDE is high, with global estimates ranging from 5% to 50% of the adult population, and the economic burden of the disease is projected to increase with aging. Worldwide, ocular lubricants are often used for the initial management of DED, but do not address the underlying causes of the disease. Potentially more effective ophthalmic pharmacological agents targeting various distinct pathophysiological pathways in DDE have been investigated over the past two decades, but these efforts have resulted in very few approved new drugs. The main approved treatments include unit doses of cyclosporine A 0.05% ophthalmic emulsion (Restasis®; Allergan, Irvine, CA, USA) and lifitegrast 5.0% ophthalmic solution (Xiidra®; Shire, Lexington, USA) in North America, cationic emulsion (Ikervis®; Santen Pharmaceutical, Osaka, Japan) in Europe, diquafosol 3% ophthalmic solution (Diquas®; Santen Pharmaceutical, Osaka, Japan) in Asia, and rebamipide 2% ophthalmic suspension (Mucosta®; Otsuka Pharmaceutical, Tokyo, Japan). In the United States (August 2018), a nanomicelle formulation of cyclosporine A 0.09% (Cequa™; Sun Pharmaceuticals, Mumbai, India) has been approved to increase tear production in patients with DED. Overall, these agents reduce inflammation on the ocular surface or stabilize the tear film, but it is unclear which agent is most suitable for patients with aqueous-deficient DED (ADDE) or evaporative DED. Gougerot-Sjogren syndrome (or Gougerot-Sjogren syndrome) (SGS) is associated with xerophthalmia due to progressive destruction of the lacrimal gland that may cause severe keratitis. SGS is a chronic disease of autoimmune origin characterized by inflammatory and progressive degenerative changes in the exocrine glands and may be associated with systemic lesions that affect the joints, skin, lungs, kidneys, or peripheral nerves in different ways. The pathophysiology of the disease is characterized by infiltration of the salivary and lacrimal glands by CD4+ T and B lymphocytes.The local activation and proliferation of these lymphocytes induces the release of proinflammatory cytokines that maintain a chronic inflammatory state, as well as the secretion of autoantibodies, ultimately leading to the apoptotic death of epithelial cells.
[0007] Seasonal and perennial allergic conjunctivitis (ocular allergies) are characterized by itchy, red, swollen, and watery eyes. Acute symptoms of allergic conjunctivitis are characterized by clinical signs or symptoms such as itchy, red, and swollen eyes. Late-stage allergic conjunctivitis or allergic inflammatory reactions include redness (redness), swelling of the eyelids, and tears. Allergic conjunctivitis and rhinoconjunctivitis may also coexist with other extrinsic ocular effects and diseases such as dry eye and irritation caused by pollutants or other causes. This leads to dysfunction of the tear film, which serves to protect the ocular surface from allergens. Ocular allergies are the main cause of dry eye. Many treatments exist to treat allergic conjunctivitis, but no treatments exist to treat dry eye caused by allergic conditions.
[0008] The usual initial management of dry eye syndrome, regardless of etiology, is based on the following: - Correction of contributing factors whenever possible (medications, environmental factors, eye drops containing preservatives (especially quaternary ammonium) etc.); and - Alternative treatment with tear substitutes (artificial tears in eye drops, gels, and medical devices with viscoelastic solutions used after the other two methods have failed).
[0009] Once dry eyes begins, they progress despite alternative therapies and persist according to the concept of a vicious circle of inflammation in which all tissues of the ocular surface, including the cornea, are gradually affected. In severe cases, xerophthalmia can cause extensive corneal damage (or keratitis), which produces a range of symptoms from a foreign body sensation and tingling on the ocular surface to persistent pain with reduced vision. The severity of xerophthalmia is related to the degree of keratitis, the inflammatory component, and the ocular symptoms.
[0010] To treat the causes of the vicious cycle that leads to dry eye, several pharmacological targets need to be treated, thus restoring tear production from the lacrimal gland as well as electrolyte secretion from the corneal epithelium.
[0011] A paper published in 2001 showed that CFTR is involved in electrolyte secretion in an immortalized rabbit corneal epithelial cell line (Non-Patent Document 2). Not only that, but it also affects the secretion of lacrimal glands (Non-Patent Document 3). In this paper, the authors show that a CFTR modulator can increase tear secretion in mice with normal CFTR.
[0012] CFTR is a cAMP / ATP-mediated anion channel expressed in various cell types, including secretory epithelial cells, that controls the flow of anions across membranes as well as the activity of other ion channels and proteins. In epithelial cells, normal function of CFTR is essential for maintaining electrolyte transport throughout the body, including respiratory and digestive tracts, and even ocular tissues. CFTR is composed of approximately 1480 amino acids, forming a protein composed of repeating transmembrane domains, each of which contains six transmembrane helices and a nucleotide-binding domain. The two transmembrane domains are linked by a large regulatory polarity domain [R] that contains several phosphorylation sites that control the activity of the channel and cellular trafficking.
[0013] Chloride transport occurs through the coordinated activity of ENaC and CFTR present in the apical membrane of the cell, and Na+ and K+ ATPases and Cl- channels expressed on the basolateral surface of the cell. Secondary active chloride transport on the luminal side results in the accumulation of intracellular chloride, which can passively exit the cell via Cl- channels, resulting in transport from the basolateral pole to the apical pole. Thus, water that is probably not actively transported is transported across the epithelium according to the transepithelial osmotic gradient generated by sodium and chloride fluxes.
[0014] There is a need to identify novel therapeutic approaches that regulate and activate normal CFTR function to treat causes of dry eye that are likely the result of insufficient CFTR function.
[0015] Allergic conjunctivitis is one of the most common allergic diseases worldwide. Its incidence is rising due to climate change, pollution, increased pollen levels, and the subject's enhanced immunological sensitivity to these environmental changes. The pathophysiology mainly involves the activation of mast cells (or mast cells) bound to immunoglobulin E, the release of histamine and other mediators that contribute to the spread of the response, including other immune cells, and subsequent inflammation.
[0016] Allergic conjunctivitis (AC) is increasing in prevalence worldwide. Itchy eyes are a characteristic symptom of AC and allow AC to be differentiated from other eye diseases caused by non-allergic stimuli.
[0017] Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (APC) are the most common forms of ocular allergy subgroups, with an estimated prevalence of 15-25% of the American population (Non-Patent Document 4). In Europe, allergic conjunctivitis is on the rise, possibly due to the introduction of ragweed, affecting up to 50% of the population (Non-Patent Document 5). Patients with AC usually have itching, tearing, burning, vasodilation, and symmetrical conjunctival edema. Spring keratoconjunctivitis (SKC) is a chronic, pathological keratoconjunctivitis that can be vision-threatening. These different chronic allergic pathologies are often accompanied by dry eye syndrome (Non-Patent Document 6).
[0018] A number of treatments are used, including antihistamine eye drops, cortisone eye drops, and immunosuppressant eye drops such as cyclosporine.
[0019] There are no treatments specifically directed at ocular allergies and their consequences, such as dry eye.
[0020] There is an urgent need to find solutions to treat both allergic eye inflammation as well as its consequences.
[0021] There is a need to find novel therapeutic approaches that not only regulate and activate CFTR function but also prevent mast cell degranulation to treat the underlying cause of the disease. [Prior art documents] [Non-patent literature]
[0022] [Non-Patent Document 1] Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review. Holland EJ, et al. Ocul Surf. 2019 [Non-Patent Document 2] Invest Ophthalmol Vis Sci. 2001 Sep Activation of a CFTR-mediated chloride current in a rabbit corneal epithelial cell line. Al-Nakkash L [Non-Patent Document 3] Invest Ophthalmol Vis Sci. 2018 Jan Novel Insight Into the Role of CFTR in Lacrimal Gland Duct Function in Mice. Berczeli O. [Non-Patent Document 4] Ono et al., 2005, Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol [Non-Patent Document 5] Burbach G., et al. 2009, Ragweed sensitization in Europe LEN study suggests increasing prevalence. Allergy [Non-Patent Document 6] Villani et al., Ocular allergy dry eye, Curr Opin All CLin Immunol, 2018 Summary of the Invention [Means for solving the problem]
[0023] The present invention relates to novel compounds, including opioid compounds and pharma- ceutically acceptable salts thereof.
[0024] The present inventors have discovered the surprising properties of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one or noscapine (see Figure 1) for modulating CFTR.
[0025] The present invention also relates to pharmaceutical compositions comprising at least one of the compounds described herein and / or at least one of their pharma- ceutically acceptable salts, which compositions may further comprise at least one other active pharmaceutical ingredient and / or at least one excipient.
[0026] The present invention also relates to a method for treating dry eye, allergic conjunctivitis, or Gujro-Sjogren's syndrome (or Gougerot-Sjogren's syndrome), comprising administering to a subject in need thereof at least one of the compounds described herein and / or at least one of their pharma- ceutically acceptable salts, optionally as part of a pharmaceutical composition containing at least one additional ingredient.
[0027] Noscapine is a chemical known for a long time and has been used as an antitussive. It is a non-narcotic isoquinolinephthalide alkaloid obtained from the opium poppy (Papaver somniferum) and has mild analgesic, antitussive, and antineoplastic properties. Noscapine exerts its antitussive effects by activating sigma opioid receptors. The drug is believed to exert its antimitotic effects by binding to tubulin, disrupting the dynamics of microtubule assemblies and subsequently inhibiting mitosis, leading to tumor cell death.
[0028] Therapeutically effective doses primarily address the undesirable effects of codeine, which, apart from occasional nausea, are negligible. Doses up to 90 mg per day have no effect on human respiration.
[0029] Noscapine is a benzylisoolein alkaloid substituted at position 1 with a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group, at positions 6 and 7 with methylenedioxy groups, and at position 8 with a methoxy group. It is obtained from the poppy family, but has no significant analgesic properties and is used primarily for its antitussive effects. Noscapine, with the molecular formula C22H23NO7, has a molecular weight of 413. The compound can be modified or substituted with compounds containing either carbon-14 or deuterium compounds.
[0030] Isotopically labeled compounds and salts can be used in a variety of ways. They can be suitable for drugs and / or various types of tests, such as tissue-on-substrate distribution tests. For example, tritium and / or carbon-14 labeled compounds are particularly useful for various types of tests, such as tissue-on-substrate distribution tests, because they are relatively easy to prepare and have good detectability. For example, deuterium-labeled products are therapeutically useful and have potential therapeutic advantages compared to non-deuterium-labeled compounds. In general, deuterium-labeled compounds and salts can have higher metabolic stability than non-isotopically labeled ones due to isotopic kinetic effects. Higher metabolic stability translates directly into longer half-lives and smaller doses in vivo, which may be desirable. Isotopically labeled compounds and salts can generally be prepared according to procedures described in known synthesis schemes. There are relevant descriptions in the worldwide literature, such as European Patent No. 3352757. Thus, it is easy to replace non-deuterated methyl with deuterated methyl. Noscapine is in the form of a white crystalline powder. It is insoluble in water, but soluble in benzene and acetone. The salts formed with acids are dextrorotatory.
[0031] The inventors have demonstrated that noscapine not only exerts a critical effect on CFTR, but also inhibits degranulation of basophils, the cell counterparts of mast cells, a dual action that is essential for treating allergic and dry eye.
[0032] Although many patents have been filed for noscapine, none have described its activity for dry eye or allergic eye. [Brief description of the drawings]
[0033] [Figure 1] 1 depicts the chemical structure of noscapine. [Diagram 2] Noscapine activity at the apical pole expressed as a percentage of the maximum effect. [Diagram 3] Noscapine activity at the basolateral pole expressed as a percentage of the maximal effect. [Figure 4] Effect of noscapine on lacrimal gland epithelial cells expressed in μA / Cm2 at the apical pole (A=forskolin; B=noscapine; C=Inh172). [Diagram 5] Effect of noscapine on lacrimal gland epithelial cells expressed as mA / Cm2 at the basolateral pole (A=forskolin; B=noscapine; C=Inh172). [Figure 6] Lacrimal functional unit based on DARTT 2002. [Figure 7] Positive control, flow cytometry analysis showing basophil degranulation by anti-IgE receptor, anti-FcεRI antibody (CD63+ and CCR3+). [Figure 8] Negative Controls in Flow Cytometry [Figure 9] Inhibition of basophil degranulation by noscapine (10 μM). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] The present inventors have uncovered surprising and unexpected properties of noscapine in a human cell model of mutation-free CFTR regulation.
[0035] The present invention thus relates to the use of the chemical substance: levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts, for use in the treatment of diseases associated with a decrease in the secretion of epithelial cells of the conjunctival tissue, the lacrimal gland and the meibomian gland.
[0036] The present invention also relates to the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for use in the treatment of diseases associated with ocular allergy.
[0037] Accordingly, the present invention relates to the use of the chemical compound: levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma-ceutically acceptable salts thereof, for use in the treatment of dry eye disease.
[0038] Thus, the present invention relates to the use of the levo- and dextro-enantiomers of the chemical compound: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutical acceptable salts, for use in the treatment of dry eye disease associated with Gujro-Sjogren's disease (or Gougerot-Sjogren's disease) and secondary Gujro-Sjogren's syndrome associated with autoimmune diseases such as rheumatoid polyarthritis or systemic lupus erythematosus.
[0039] The present invention thus relates to the use of the chemical compound: the levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts, for use in the treatment of allergic conjunctivitis accompanied by reduced tear film secretion.
[0040] Thus, the present invention relates to the use of the levo- and dextro-enantiomers of the chemical compound: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for use in the treatment of vernal keratoconjunctivitis.
[0041] The present invention therefore relates to the use of the chemical compound: the levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts, for use in the treatment of dry eye disease, characterized in that it is administered in the form of eye drops or eye ointment.
[0042] Thus, the present invention relates to the use of the chemical compound: levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts, for use in the treatment of dry eye disease and / or allergic eye disease, characterized in that it is administered as eye drops in a dose of 0.1 milligrams to 5 milligrams.
[0043] According to a preferred embodiment, the present invention relates to the use of the levorotatory and dextrorotatory enantiomers of the chemical substance (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for the treatment of dry eye disease, characterized in that they are administered in the form of eye drops in combination with hyaluronic acid or carbomer-based wetting agents and lubricants. These compounds have the ability to increase the duration of the effect of noscapine. According to a preferred embodiment, the present invention relates to the use of the chemical entity: levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts, characterized in that at least one of the methyls is replaced by a deuterated methyl, for use in the treatment of dry eye disease and / or allergic eye disease. The present invention also relates to the levo- and dextro-enantiomers of a chemical compound: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutical acceptable salts thereof, for use in improving ion transport at the apical and basolateral poles of corneal epithelial cells, eyelid epithelial cells, lacrimal epithelial cells and / or meibomian gland epithelial cells.
[0044] According to a preferred embodiment of the invention, the chemical entity is substituted at its methyl groups with deuterated methyl to improve pharmacokinetics.
[0045] According to a preferred embodiment, the present invention relates to the levorotatory and dextrorotatory enantiomers of the chemical compound: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof, for use in the treatment of dry eye disease at a dose of 0.1 milligrams to 5 milligrams per day.
[0046] According to a preferred embodiment, the present invention relates to the chemical substance levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for use in the treatment of dry eye, characterized in that it is packaged in the form of eye drops or eye ointment. EXAMPLES
[0047] To investigate this effect on CFTR regulation, we used the Ussing chamber technique, invented by the Danish Hans H. Ussing in the late 1950s. This technique allows the tissue of interest to be kept alive for several hours under controlled temperature and medium conditions, making it possible to study ion exchange across the epithelium. By placing the tissue between two half-chambers, it is possible to define an apical compartment (corresponding to the lumen of the organ) and a basolateral compartment (corresponding to the blood compartment) and to study the exchange between these two compartments across the tissue.
[0048] This technique is commonly used and is particularly suitable for exploring pharmacological approaches of ion transport and therapeutically interesting molecules associated with ion secretion from epithelial cells. It involves measuring the transepithelial current (called short circuit current and denoted Ise). Ise is expressed in amperes per unit surface area of the epithelium (Ise in μA / cm2). To mimic conditions close to in vivo, cells are cultured on porous filters for 10-15 days at the liquid-liquid interface and then at the air-liquid interface. During the culture, the transepithelial resistance is measured periodically. The higher this resistance (several hundred Ω), the more continuous, polarized and therefore dense the epithelial tissue is. At the air (apical)-liquid (basolateral) interface, the epithelial cells are polarized and form a tight mat, which can be studied with the Ussing chamber method. We used a system with six chambers from Physiologie Instrument®, which allows to perform six experiments in parallel.
[0049] In our studies, the following materials and molecules were used: Amiloride: final concentration 100 μM; 100 mM stock solution, in water (supplied by Sigma®). Forskolin: final concentration 0.05 μM; 1 mM stock solution, DMSO solvent (supplier: Sigma®). Genistein: final concentration 30 μM; 30 mM stock solution, DMSO solvent (supplied by Sigma®). CFTR inhl72: final concentration 10 μM; 10 mM stock solution, DMSO solvent (source: Fisher®). UTP: final concentration 100 μM; 100 mM stock solution, DMSO solvent (source: Sigma®).
[0050] We used a variety of media and reagents, including supports suitable for Ussing chambers: Snapwell (Fisher®), culture medium (Gibco®), SVF (Gibco®), puromycin (Gibco®), T75 culture flasks (Fisher®).
[0051] We used the USSING chamber to analyze the activity of noscapine on CFTR in glandular epithelial cells.
[0052] Standard protocol used for human epithelial cells expressing non-mutated CFTR: - Measurement of the short circuit current in the presence of amiloride (an inhibitor of the ENaC channel, 100 μM), with the addition of 10 μM of noscapine molecules, then the addition of CFTR inhl72 (10 μM, a CFTR inhibitor), then the addition of UTP (100 μM, to validate the experiment by activating the sensitive calcium C1 transporter). - Measurement of the short circuit current in the presence of amiloride (100 μM) and forskolin (0.05 μM, activator of intracellular cAMP) upon addition of 10 μM of noscapine molecules, followed by addition of CFTR inhl72 (10 μM) and then addition of UTP (100 μM). - Measurement of short circuit current in the presence of CFTR Inhl72 (10 μM) and addition of noscapine and forskolin (0.05 μM) followed by addition of UTP.
[0053] We prepared a 100 μM stock solution in DMSO. Compounds were dispensed in 100 μL aliquots and stored at −20° C.
[0054] Noscapine was added to USSING cells at a dose of 10 μM relative to non-mutated cells [Figure 5].
[0055] The effect of noscapine on non-mutated epithelial cells at the apical side is significant as the delta increases from 16 to over 20 (expressed in μA / cm2).
[0056] Addition of forskolin changes the potential from 20 to 27 (expressed in μA / cm2).
[0057] Addition of Inh172 completely blocks the cell potential.
[0058] Noscapine activates cell potentials in lacrimal epithelial cells expressing native CFTR, an effect that is additive with that of forskolin.
[0059] The effect of noscapine on apical non-mutated lacrimal epithelial cells is significant, as the difference increases from 6.5 to over 7.5 (expressed in μA / cm2).
[0060] The addition of forskolin alters the potential, which switches from 3.5 to 6.5 (expressed in μA / cm 2 ).
[0061] Addition of Inh172 completely blocks the cell potential.
[0062] In conclusion, noscapine activates ion transport in lacrimal epithelial cells.
[0063] This effect is blocked by inh172, which specifically inhibits CFTR ion transport.
[0064] Noscapine is believed to be a molecule that can stimulate ion transport through non-mutated CFTR.
[0065] Next, we determined the effective dose of noscapine at both the apical and basolateral poles.
[0066] As a result, the EC50 activity at the apical pole was 3.42±0.19 μM, and the EC50 at the basolateral pole was 4.87±0.27 μM ([Figure 2], [Figure 3]).
[0067] Thus, noscapine can improve tear secretion function in patients with established dry eye pathologies, including not only Gujro-Sjögren's disease (or Gougerot-Sjögren's disease) but also so-called "secondary" Gujro-Sjögren's syndrome associated with certain autoimmune diseases such as rheumatoid polyarthritis and systemic lupus erythematosus.
[0068] To demonstrate the effect of noscapine on allergic eye, the inventors investigated basophils, a cellular model of allergy. Basophils, as well as mast cells, are found in the conjunctival mucosa. Human adipocytes and polynuclear basophils have relatively similar morphological appearances and originate from the same CD34+ hematopoietic stem cells.
[0069] Whereas mast cells are tissue-resident elements, basophils are circulating cells that are found in epithelial tissues during major allergic events (Kepley et al., J Respir Crit Care Med. 2001. Immunohistochemical detection of human basophils in post mortem cases of fatal asthma).
[0070] These two cells are involved in IgE-dependent allergic reactions; they express high-affinity IgE receptors. Nevertheless, the mediators released by these cells during this activation differ in some respects. Furthermore, basophils and especially mast cells are involved in innate immunity. Thus, basophils and mast cells have many common features, more specifically the secretion of IL4 and IL13, which are known to stimulate collagen synthesis and induce the proliferation of fibroblasts, which leads to fibrosis. Fibrosis may affect the meibomian gland in dry and allergic eyes. Basophils, unlike mast cells with most of their characteristics, are present in the circulating blood. To investigate the effect of noscapine on basophils, we used a commercially available kit from BULHMANN Laboratories AG (Switzerland), the Flow CAST® kit. This kit is a basophil activation test (TAB) that can be used not only for the in vitro detection of basophil degranulation, but also for the study of immediate allergic reactions and hypersensitivity.
[0071] It is designed for the in vitro diagnosis of the expression of the CD63 marker as a surface marker of activated basophils. The test is performed in whole blood; by flow cytometry, the expression of CD63 on the surface of activated basophils can be quantified (www.buhlmannlabs.ch).
[0072] We used the CAST Kit-Flow (www.buhlmannlabs.ch / products-solutions / cellular-allergy / flow-cast / ) to test the effect of noscapine on inhibiting basophil degranulation. Basophil activation (or degranulation) can be achieved in three different ways: by allergens, by "anti-IgE" (anti-FcεRI, the anti-IgE receptor), or by a bacterial lipopolysaccharide antigen called fMLP. At steady state, basophils express very little CD63 antigen, as it is bound to granules in the cytoplasm.
[0073] Activation of basophils (eg, by IgE (immunological activation) or fMLP (non-immunological activation)) causes the granules to fuse with the cell membrane, thus resulting in the expression of CD63 on the surface of the cell.
[0074] To assess degranulation, the Flow CAST® kit was used in part. This test involves anti-IgE to the IgE receptor.
[0075] CCR3 is a gene-encoded protein that is a receptor for CC-type chemokines. It belongs to the G protein-coupled receptor family 1. It is highly expressed in eosinophils, basophils, and is also detected in TH1 and TH2 cells, as well as epithelial cells.
[0076] Flow cytometry is used to characterize the different blood cells. The laser beam allows the evaluation and measurement of different cell parameters. A head-on measurement of the diffracted light of the laser beam allows the evaluation of the cell size: this is the forward scatter (FSC). A measurement of the light diffracted perpendicularly allows the evaluation of the cell granularity: this is the side scatter (SSC).
[0077] This granularity can be due to the irregularity of the interior or surface of the cell, or the density of the organelles that compose it (ass.ens-lyon.fr). Fluorescent markers then allow to better characterize the various cell subpopulations (these markers are jointly called clusters of differentiation (CD)). We opted for a degranulation protocol. Four patients were therefore randomly selected among those who had undergone the collection of a conventional blood sample (NF) in a medical-biological laboratory. As a note, when basophils are activated, the CD63 marker bound to the intracytoplasmic granules fuses with the cell membrane. They are then expressed at the surface of the cell: activated basophils therefore become CD63+. In addition to CD63, another marker specific for basophils allows to target them better: this is CCR3 (chemokine receptor 3). The latter is always expressed by this type of cell. Activated and degranulated basophils are CD63+ and CCR3+; non-degranulated basophils are CD63- and CCR3+. First, we defined a "negative control" sample, a sample containing only neutral buffer. The latter was analyzed to observe the results expected in the absence of stimulation and therefore degranulation. In Figure 8, we can see that only the CD63-CCR3+ region (blue) contains points corresponding to non-degranulated basophils.
[0078] Thus, in the absence of stimulation, the cells are not activated and do not degranulate. A positive control sample is performed using FcsRI antibody.
[0079] The window (positive control sample with anti-FceRI antibody) makes it possible to observe puncta in the CD63+CCR3+ area (red). The product used (anti-FceRI antibody) actually induces degranulation of basophils (see [Figure 7]).
[0080] FIG. 9 shows that noscapine blocks the activation of basophil degranulation caused by anti-FceRI antibodies.
[0081] It can be said that noscapine has the surprising effect of inhibiting degranulation mediated by stimulation of the IgE receptor.
[0082] Thus, in dry eye, noscapine would have two actions: one on basophils, and therefore on mast cells, by preventing degranulation, and the other on CFTR. The action on degranulation would prevent the inflammatory reaction, and the action on normal CFTR would allow the secretion of the lacrimal gland as well as that of the conjunctival epithelial cells to resume. Thus, the tear film, which is very unstable and strongly disturbed in dry eye, would be reconstituted.
[0083] Thus, the topical effects of noscapine on dry eye appear to be remarkable and surprising due to its dual pharmacological actions: its effect on CFTR and its inhibition of basophil and mast cell degranulation. Finally, preferred embodiments of the present invention are described in sections. [Embodiment 1] Levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof for use in the treatment of diseases associated with reduced secretion of conjunctival epithelial cells, lacrimal glands and meibomian glands. [Embodiment 2] Levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof for use in the treatment of diseases associated with ocular allergy. [Embodiment 3] Levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof according to embodiments 1 and 2 for use in the treatment of dry eye disease. [Embodiment 4] The levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutical acceptable salts according to embodiment 2 for use in the treatment of allergic eye diseases associated with vernal conjunctivitis. [Embodiment 5] The levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof according to embodiment 3 for use in the treatment of dry eye disease associated with autoimmune diseases such as rheumatoid polyarthritis, systemic lupus erythematosus, and Gujrov-Sjogren's disease. [Embodiment 6] The levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof according to embodiment 2 for use in the treatment of dry eye disease in the treatment of allergic conjunctivitis accompanied by reduced tear film secretion. [Embodiment 7] Levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and pharma- ceutically acceptable salts thereof according to any one of embodiments 2 to 6 for use in the treatment of dry eye disease, characterized in that it is administered in a dose of 0.1 to 5 mg / day. [Embodiment 8] The levo- and dextro-enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for use according to any one of embodiments 1 to 7, characterized in that they are combined with a carbomer-based wetting agent or a hyaluronic acid-based lubricant. [Embodiment 9] Levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for use according to any one of embodiments 1 to 8, characterized in that at least one of the methyl groups is substituted with a deuterated methyl. [Embodiment 10] The levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one and its pharma- ceutically acceptable salts for use according to any one of embodiments 1 to 9, characterized in that they are packaged in the form of eye drops or eye ointment.
Claims
1. A composition for use in the treatment of a disease associated with reduced secretion from conjunctival epithelial cells, lacrimal glands and meibomian glands, comprising (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one or an enantiomer thereof, or a pharma- ceutically acceptable salt thereof.
2. A composition for use in the treatment of a disease associated with ocular allergy, comprising (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one or an enantiomer thereof, or a pharma- ceutically acceptable salt thereof.
3. 3. A composition according to claim 1 or 2 for use in the treatment of dry eye disease.
4. 3. The composition of claim 2 for use in the treatment of allergic eye disease associated with vernal conjunctivitis.
5. 4. The composition of claim 3 for use in the treatment of dry eye disease associated with autoimmune diseases such as rheumatoid polyarthritis, systemic lupus erythematosus, and Gujlow-Sjogren's disease.
6. 3. The composition of claim 2 for use in the treatment of dry eye disease in the treatment of allergic conjunctivitis accompanied by reduced tear film secretion.
7. 7. A composition according to any one of claims 2 to 6 for use in the treatment of dry eye disease, wherein a dosage of 0.1 to 5 mg / day of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one or an enantiomer thereof, or a pharma- ceutically acceptable salt thereof is administered.
8. 8. The composition of any one of claims 1 to 7, wherein (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one or an enantiomer thereof, or a pharma-ceutically acceptable salt thereof is combined with a carbomer-based wetting agent or a hyaluronic acid-based lubricant.
9. The composition according to any one of claims 1 to 8, wherein (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one or an enantiomer thereof, or a pharma- ceutically acceptable salt thereof, is substituted with deuterated methyl at at least one of the methyl groups.
10. The composition according to any one of claims 1 to 9, which is packaged in the form of eye drops or eye ointment.
Citation Information
Patent Citations
Pharmaceutical composition containing buprenorphine
JP2009516687A
ophthalmological treatment
JP2014513073A
CFTR Regulators and Methods of Use Thereof
JP2019505502A
Noscapine and analogs and methods related thereto
US20120053199A1
